Proteasome Activity in Parkinsonism through D1 Dopamine Receptor

Authors

  • R. B. Jiménez Neuroscience and Biotechnology Laboratory, School of Medicine, Universidad Panamericana, México DF, México
  • J.E. Telich-Tarriba Neuroscience and Biotechnology Laboratory, School of Medicine, Universidad Panamericana, México DF, México
  • J.D. Carrillo-Ruíz Department of Neuroscience and Psychophysiology, Universidad Anahuac, Mexico, Neurosurgery Clinic of Spasticity, Service Functional Neurosurgery and Radiosurgery Hospital General de México
  • G. Rivera-Silva Tisular Engineering and Regenerative Medicine Laboratory, University of Monterrey, San Pedro Garza García, NL, México

Keywords:

L-DOPA, Antiparkinsonian drugs, Ubiquitine-proteosome system, Akinetic symtoms

Abstract

As of today, L-DOPA is recognized as the most efficacious drug to alleviate the typical signs and symptoms of Parkinson disease (PD). It is most effective for the akinetic symtoms, and its use is indicated when the disease becomes disabling or it cannot be controlled by other antiparkinsonian drugs. Unfortunately, response to medication changes during the progression of the disease, with the patients developing tolerance to treatment and the need for higher doses that lead to the development of side effects. The Ubiquitine-proteosome system (UPS) is key in regulating the degradation of normal and abnormal intracellular proteins linked to signal transduction, cell cycle progression, apoptosis and differenciation; therefore it dysregulation would be expected to impact several systems. UPS dysregulation has been implicated in cancer, neurodegenerative and autoimmune diseases.

References

Ahlskog, J.E., Muenter, M.D., 2001. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord.16(3), 448.

Bagetta, V., Ghiglieri, V., Sgobio, C., Calabresi, P., 2010. Picconi B.Synaptic dysfunction in Parkinson's disease.Biochem Soc Trans. 38(2), 493-7.

Berthet, A., Bezard, E., Porras, G., Fasano, S., Barroso-Chinea, P., Dehay, B., Martinez, A., Thiolat, M.L., Nosten-Bertrand, M., Giros, B., Baufreton, J., Li, Q., Bloch, B., Martin-Negrier, M.L., 2012. L-DOPA impairs proteasome activity in parkinsonism through D(1) dopamine receptor. J Neurosci. 11, 32(2), 681-91.

Cook, C., Petrucelli, L.A., 2009. Critical evaluation of the ubiquitin-proteasome system in Parkison’s disease. Biochim Biophys Acta. 1792(7), 664-675.

Francois, J.G., 2009. Vingerhoets. Diskinesia in Parkinson disease: Back for the future? Neurol. 72, 1202-1203.

Rylander, D., Parent, M., O'Sullivan, S.S., Dovero, S., Lees, A.J., Bezard, E., Descarries, L., 2010. Cenci MA.Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.Ann Neurol. 68(5). 619-28.

Troiano, A.R., de la Fuente-Fernandez, R., Sossi, V., Schulzer, M., Mak, E., Ruth, T.J., Stoessl, A.J., 2009. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurol. 72, 1211 – 1216.

Downloads

Published

2013-01-29

How to Cite

B. Jiménez, R., Telich-Tarriba, J. ., Carrillo-Ruíz, J. ., & Rivera-Silva, G. . (2013). Proteasome Activity in Parkinsonism through D1 Dopamine Receptor. Scientific Journal of Pure and Applied Sciences, 2(1), 54-56. Retrieved from http://sjournals.com/index.php/sjpas/article/view/1009

Issue

Vol. 2 No. 1 (2013): January

Section

Medicine

License

Copyright (c) 2013 R. B. Jiménez, J.E. Telich-Tarriba, J.D. Carrillo-Ruíz, G. Rivera-Silva

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.